We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PHUN:NASDAQPhunware, Inc. Analysis

Data as of 2026-06-14 - not real-time

$1.93

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Phunware’s stock is trading at $1.93, barely above the computed support of $1.90 and well below the 20‑day SMA of $2.00, indicating limited upside momentum. The 20‑day SMA sits beneath the 50‑day ($2.05) and 200‑day ($2.14) averages, a classic bearish alignment, while the RSI of 44 suggests the price is not yet oversold. MACD is negative with the line below the signal, reinforcing a downtrend, yet volume is increasing, hinting at potential accumulation. Volatility is extreme at over 53% for the past 30 days and a beta of 2.22 signals high sensitivity to market swings, compounded by a historic max drawdown of 54%. Fundamentals are weak: negative earnings, a forward PE of –3.71, operating losses and zero dividend. However, recent material news announces a new CEO, Dmitry Kroshka, and an AI‑driven hospitality platform upgrade, which could catalyze a strategic turnaround.
While the valuation appears cheap relative to book (P/B 0.42) and the market cap is modest, the combination of bearish technicals, high risk metrics, and unprofitable operations suggests caution. Investors should monitor the execution of the AI platform and any revenue uplift before committing, as the upside potential remains limited without clear earnings improvement.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish technical alignment (SMA hierarchy, MACD)
  • Proximity to support level
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential revenue lift from AI hospitality platform
  • Continued cash burn and negative earnings
  • Improving volume trend

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic leadership change and product roadmap
  • Undervalued book value relative to price
  • Long‑run upside if profitability can be restored

Key Metrics & Analysis

Financial Health

Revenue Growth-21.20%
P/E Ratio-3.7
ROE-11.04%
ROA-11.65%
Debt/Equity0.58
P/B Ratio0.4
Op. Cash Flow$-11859000
Free Cash Flow$-13130375
Industry P/E36.8

Technical Analysis

TrendBearish
RSI43.6
Support$1.90
Resistance$2.20
MA 20$2.00
MA 50$2.05
MA 200$2.14
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Target Price$2.00
Upside/Downside3.63%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.22
Volatility53.73%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.